FR23C1005I1 - VACCINES AGAINST FLAVIVIRUS - Google Patents

VACCINES AGAINST FLAVIVIRUS

Info

Publication number
FR23C1005I1
FR23C1005I1 FR23C1005C FR23C1005C FR23C1005I1 FR 23C1005 I1 FR23C1005 I1 FR 23C1005I1 FR 23C1005 C FR23C1005 C FR 23C1005C FR 23C1005 C FR23C1005 C FR 23C1005C FR 23C1005 I1 FR23C1005 I1 FR 23C1005I1
Authority
FR
France
Prior art keywords
vaccines against
against flavivirus
flavivirus
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1005C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29739394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1005(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of FR23C1005I1 publication Critical patent/FR23C1005I1/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FR23C1005C 2002-01-15 2023-01-12 VACCINES AGAINST FLAVIVIRUS Active FR23C1005I1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34894902P 2002-01-15 2002-01-15
US38528102P 2002-05-31 2002-05-31
EP10013094A EP2295023A1 (en) 2002-01-15 2003-01-15 Flavivirus vaccines
PCT/US2003/001214 WO2003103571A2 (en) 2002-01-15 2003-01-15 Flavivirus vaccines
EP03748884A EP1471873A4 (en) 2002-01-15 2003-01-15 Flavivirus vaccines

Publications (1)

Publication Number Publication Date
FR23C1005I1 true FR23C1005I1 (en) 2023-03-24

Family

ID=29739394

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1005C Active FR23C1005I1 (en) 2002-01-15 2023-01-12 VACCINES AGAINST FLAVIVIRUS

Country Status (14)

Country Link
US (5) US7459160B2 (en)
EP (3) EP3679915B1 (en)
JP (2) JP2005519639A (en)
KR (2) KR101194818B1 (en)
CN (1) CN103555669B (en)
AU (1) AU2003267937C1 (en)
BR (3) BRPI0306905B8 (en)
CA (1) CA2473321C (en)
ES (1) ES2924640T3 (en)
FR (1) FR23C1005I1 (en)
IL (3) IL163001A (en)
MX (1) MXPA04006870A (en)
NZ (1) NZ534159A (en)
WO (1) WO2003103571A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
KR100921592B1 (en) 2001-06-01 2009-10-14 사노피 파스테르 바이오로직스 씨오 Chimeric flavivirus vectors
BRPI0306905B8 (en) 2002-01-15 2021-05-25 Acambis Inc method of producing an immunogenic/dengue composition comprising a flavivirus
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
ES2337893T3 (en) 2002-11-15 2010-04-30 Sanofi Pasteur Biologics Co. VACCINE OF THE WESTERN NILE VIRUS.
CA2582534A1 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
US8124398B2 (en) 2005-04-24 2012-02-28 Sanofi Pasteur Biologics Co. Recombinant flavivirus vaccines
AU2013204985B2 (en) * 2005-04-24 2016-01-28 Sanofi Pasteur Biologics, Llc Recombinant flavivirus vaccines
FR2906724B1 (en) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa METHOD OF IMMUNIZATION AGAINST THE 4 SEROTYPES OF DENGUE.
EP2535058A3 (en) 2006-11-07 2013-04-10 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
BRPI0909820A2 (en) 2008-03-05 2015-08-11 Sanofi Pasteur Process for stabilizing influenza vaccine composition, for stabilizing adjuvanted-containing vaccine composition and for preparing vaccine, vaccine compositions, vaccine kit and stockpiling method
EP2143440A1 (en) 2008-07-09 2010-01-13 Sanofi Pasteur Stabilising agent and vaccine composition comprising one or several attenuated living flavivirus
EP2550292B1 (en) * 2010-03-24 2017-11-22 Research Development Foundation Flavivirus host range mutations and uses thereof
US8889148B2 (en) 2010-07-01 2014-11-18 Research Development Foundation Flavivirus host-range mutations and uses thereof
EP3932422A1 (en) * 2012-07-24 2022-01-05 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
MY187896A (en) 2013-06-21 2021-10-27 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
TW201620546A (en) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 Vaccine compositions
MY192543A (en) 2014-12-22 2022-08-26 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
WO2017005652A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US20180229407A1 (en) * 2017-02-03 2018-08-16 Marhaygue, Llc Structural Composition and Method
AU2018346724A1 (en) 2017-10-05 2020-05-14 Sanofi Pasteur Compositions for booster vaccination against dengu
AU2018388102A1 (en) 2017-12-21 2020-07-16 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
KR102269663B1 (en) 2018-04-27 2021-06-28 주식회사 레모넥스 Medicinal composition for preventing or treating flavivirus infections and method for treating the same
AU2021364852A1 (en) * 2020-10-23 2023-06-22 Sk Bioscience Co., Ltd. Vaccine composition or kit for reducing size or volume of target tissue, containing genetic material that encodes foreign antigen
WO2023204693A1 (en) * 2022-04-22 2023-10-26 에스케이바이오사이언스 주식회사 Composition for reducing size or volume of target tissue or kit including same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173418A (en) 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
DE69230316T2 (en) 1991-09-19 2000-07-13 Us Health CHIMERIC AND / OR GROWTH-INHIBITED FLAVIVIRES
US6136561A (en) * 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
US6171864B1 (en) * 1996-07-05 2001-01-09 Pioneer Hi-Bred International, Inc. Calreticulin genes and promoter regions and uses thereof
EP0977587B1 (en) * 1997-02-28 2005-06-15 Acambis Inc. Chimeric flavivirus vaccines
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
BRPI9701774B8 (en) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz mutant and infectious yellow fever virus cdna, DNA construct, recombinant yellow fever virus and human vaccine against yellow fever infections.
US6416763B1 (en) * 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
AU1813901A (en) * 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
ES2395991T3 (en) * 1999-12-03 2013-02-18 Baxter International Inc. Pyrogenicity test for use with automatic immunoassay systems
ATE526411T1 (en) 2000-02-16 2011-10-15 Us Gov Health & Human Serv AVIRULENT IMMUNOGENIC FLAVIVIRUS CHIMERA
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
KR100921592B1 (en) 2001-06-01 2009-10-14 사노피 파스테르 바이오로직스 씨오 Chimeric flavivirus vectors
US6682883B1 (en) * 2001-07-19 2004-01-27 Acambis, Inc. Diagnosis of flavivirus infection
NZ532385A (en) * 2001-10-19 2007-01-26 Acambis Inc Methods of preventing and treating flavivirus infection in animals
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
BRPI0306905B8 (en) 2002-01-15 2021-05-25 Acambis Inc method of producing an immunogenic/dengue composition comprising a flavivirus
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
ES2337893T3 (en) 2002-11-15 2010-04-30 Sanofi Pasteur Biologics Co. VACCINE OF THE WESTERN NILE VIRUS.
US7189403B2 (en) * 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
WO2005040390A1 (en) 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. A recombinant vaccine using yellow fever virus as vector
WO2005049815A1 (en) 2003-11-21 2005-06-02 K.U.Leuven Research & Development Flavivirus replication
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
US8124398B2 (en) 2005-04-24 2012-02-28 Sanofi Pasteur Biologics Co. Recombinant flavivirus vaccines
AU2006257610B2 (en) 2005-06-17 2012-11-15 Centers For Disease Control And Prevention Dengue serotype 1 attenuated strain
BRPI0504945B8 (en) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz METHOD FOR PRODUCTION OF RECOMBINANT FLAVIVIRUS CONTAINING NUCLEOTIDE SEQUENCES ENCODING A HETEROLOGOUS PROTEIN, DNA CONSTRUCT, FLAVIVIRUS, AND, VACCINE COMPOSITION TO IMMUNIZE AGAINST FLAVIVIRUS AND/OR OTHER PATHOGENS.
CN203286821U (en) 2013-05-03 2013-11-13 珠海格力电器股份有限公司 Double-stage enthalpy increasing air conditioner system

Also Published As

Publication number Publication date
WO2003103571A2 (en) 2003-12-18
IL223457A (en) 2017-07-31
US20090191240A1 (en) 2009-07-30
EP1471873A2 (en) 2004-11-03
KR101074175B1 (en) 2011-10-14
AU2003267937B2 (en) 2008-09-18
MXPA04006870A (en) 2005-05-16
WO2003103571A3 (en) 2004-04-22
BR122018075729B1 (en) 2020-02-11
EP3679915B1 (en) 2022-06-01
US20130189306A1 (en) 2013-07-25
BRPI0306905B1 (en) 2019-05-07
BR122018075729B8 (en) 2021-07-27
IL223457A0 (en) 2013-02-03
IL223458A0 (en) 2013-02-03
JP2005519639A (en) 2005-07-07
KR20040078666A (en) 2004-09-10
EP1471873A4 (en) 2005-03-16
AU2003267937C1 (en) 2019-08-08
US10172929B2 (en) 2019-01-08
JP2010268804A (en) 2010-12-02
US7459160B2 (en) 2008-12-02
ES2924640T3 (en) 2022-10-10
JP5554646B2 (en) 2014-07-23
US8852914B2 (en) 2014-10-07
CN103555669B (en) 2017-10-13
KR20110013494A (en) 2011-02-09
EP2295023A1 (en) 2011-03-16
CN103555669A (en) 2014-02-05
KR101194818B1 (en) 2012-10-25
BRPI0306905B8 (en) 2021-05-25
US20150024004A1 (en) 2015-01-22
US20080274142A1 (en) 2008-11-06
IL163001A (en) 2012-12-31
US20190192649A1 (en) 2019-06-27
NZ534159A (en) 2007-03-30
CA2473321C (en) 2015-10-06
EP3679915A1 (en) 2020-07-15
AU2003267937A1 (en) 2003-12-22
BR0306905A (en) 2005-04-12
CA2473321A1 (en) 2003-12-18
BR122018075730B1 (en) 2022-04-19

Similar Documents

Publication Publication Date Title
FR23C1005I1 (en) VACCINES AGAINST FLAVIVIRUS
MA28609B1 (en) VACCINES
IL177667A0 (en) Flavivirus vaccines
MA28639B1 (en) VACCINES
EP1804831A4 (en) Listeria-based and llo-based vaccines
MA28885B1 (en) vaccines
IL173921A0 (en) Vaccine
GB0329146D0 (en) Vaccine
GB0212046D0 (en) Vaccines
GB0323840D0 (en) Vaccines
GB0305794D0 (en) Vaccine
GB0328753D0 (en) Hepatitis B vaccines
GB0330079D0 (en) Vaccine
GB0321614D0 (en) Vaccines
GB0305793D0 (en) Vaccine
GB0304634D0 (en) Vaccines
TWI350174B (en) Adjuvanted bovine vaccines
GB0212036D0 (en) Vaccines
GB0308691D0 (en) Vaccine preparations
GB0412407D0 (en) Vaccine
GB0406598D0 (en) Vaccine
GB0330007D0 (en) Vaccines
GB0304672D0 (en) Vaccines
GB0300914D0 (en) Vaccines
GB0300397D0 (en) Vaccines